Abstract：
BACKGROUND: HER2-low populations constitute a heterogeneous group, and the cytotoxic anticancer agent efficacy based on HER2 status remains unclear. This study evaluated the clinicopathological features and outcomes of patients with advanced breast cancer showing HER2-low expression treated with eribulin or capecitabine, two treatment options after anthracycline and taxane treatment.
METHODS: We retrospectively evaluated patients who were treated with eribulin or capecitabine between 2011 and 2015. HER2 status was evaluated according to the ASCO/CAP guidelines.
RESULTS: No significant difference was observed in overall survival (OS; eribulin: hazard ratio [HR], 0.66; 95% CI 0.40-1.10; capecitabine: HR, 0.76; 95% CI 0.45-1.30) or progression-free survival (PFS; eribulin: HR, 1.13; 95% CI 0.72-1.78; capecitabine: HR, 0.90; 95% CI 0.56-1.44) between patients receiving eribulin (HER2-null: 35, HER2-low: 44) and those receiving capecitabine (HER2-null: 41, HER2-low: 33). Subgroup analysis revealed no significant differences in OS between the two groups in the hormone-positive and -negative populations for eribulin and capecitabine. HER2-null and HER2-low patients showed objective response rates (ORRs) of 22.5% and 9.1% (p = 0.09) overall, and 32.0% and 10.5% (p = 0.03), respectively, in hormone-positive cases among eribulin-treated patients. No response was observed in hormone-negative patients. Capecitabine treatment in HER2-null and HER2-low patients had overall ORRs of 26.8% and 15.2% (p = 0.23), respectively, with 27.3% and 16.1% (p = 0.28) for hormone-positive cases; and 25.0% and 0% (p = 1.0), respectively, for hormone-negative cases.
CONCLUSIONS: Eribulin and capecitabine sensitivity may vary based on HER2 expression in patients with HER2-low and HER2-null breast cancer. Prognosis was similar between the HER2-low and the HER2-null groups.
METHODS: We retrospectively evaluated patients who were treated with eribulin or capecitabine between 2011 and 2015. HER2 status was evaluated according to the ASCO/CAP guidelines.
RESULTS: No significant difference was observed in overall survival (OS; eribulin: hazard ratio [HR], 0.66; 95% CI 0.40-1.10; capecitabine: HR, 0.76; 95% CI 0.45-1.30) or progression-free survival (PFS; eribulin: HR, 1.13; 95% CI 0.72-1.78; capecitabine: HR, 0.90; 95% CI 0.56-1.44) between patients receiving eribulin (HER2-null: 35, HER2-low: 44) and those receiving capecitabine (HER2-null: 41, HER2-low: 33). Subgroup analysis revealed no significant differences in OS between the two groups in the hormone-positive and -negative populations for eribulin and capecitabine. HER2-null and HER2-low patients showed objective response rates (ORRs) of 22.5% and 9.1% (p = 0.09) overall, and 32.0% and 10.5% (p = 0.03), respectively, in hormone-positive cases among eribulin-treated patients. No response was observed in hormone-negative patients. Capecitabine treatment in HER2-null and HER2-low patients had overall ORRs of 26.8% and 15.2% (p = 0.23), respectively, with 27.3% and 16.1% (p = 0.28) for hormone-positive cases; and 25.0% and 0% (p = 1.0), respectively, for hormone-negative cases.
CONCLUSIONS: Eribulin and capecitabine sensitivity may vary based on HER2 expression in patients with HER2-low and HER2-null breast cancer. Prognosis was similar between the HER2-low and the HER2-null groups.
摘要：
背景：低HER2群体构成了一个异质群体，基于HER2状态的细胞毒性抗癌剂疗效尚不清楚.这项研究评估了使用艾瑞布林或卡培他滨治疗的HER2低表达的晚期乳腺癌患者的临床病理特征和预后。蒽环类和紫杉烷治疗后的两种治疗选择。
方法：我们回顾性评估了2011年至2015年间接受艾瑞布林或卡培他滨治疗的患者。根据ASCO/CAP指南评估HER2状态。
结果：总生存期无显著差异（OS；eribulin：风险比[HR]，0.66；95%CI0.40-1.10；卡培他滨：HR，0.76；95%CI0.45-1.30）或无进展生存期（PFS；eribulin：HR，1.13；95%CI0.72-1.78；卡培他滨：HR，0.90;95％CI0.56-1.44）在接受艾瑞布林（HER2无效：35，HER2低：44）和接受卡培他滨（HER2无效：41，HER2低：33）的患者之间。亚组分析显示，在eribulin和卡培他滨的激素阳性和阴性人群中，两组之间的OS没有显着差异。HER2无效和低HER2患者的客观缓解率（ORR）为22.5％和9.1％（p=0.09）。和32.0%和10.5%(p=0.03)，分别,在接受eribulin治疗的患者中，激素阳性病例。在激素阴性患者中未观察到反应。卡培他滨治疗HER2无效和低HER2患者的总ORR为26.8%和15.2%(p=0.23)。分别,激素阳性病例分别为27.3%和16.1%(p=0.28)；25.0%和0%(p=1.0)，分别,激素阴性病例。
结论：Eribulin和卡培他滨敏感性可能因HER2低HER2和无HER2乳腺癌患者的HER2表达而异。低HER2组和无HER2组的预后相似。
方法：我们回顾性评估了2011年至2015年间接受艾瑞布林或卡培他滨治疗的患者。根据ASCO/CAP指南评估HER2状态。
结果：总生存期无显著差异（OS；eribulin：风险比[HR]，0.66；95%CI0.40-1.10；卡培他滨：HR，0.76；95%CI0.45-1.30）或无进展生存期（PFS；eribulin：HR，1.13；95%CI0.72-1.78；卡培他滨：HR，0.90;95％CI0.56-1.44）在接受艾瑞布林（HER2无效：35，HER2低：44）和接受卡培他滨（HER2无效：41，HER2低：33）的患者之间。亚组分析显示，在eribulin和卡培他滨的激素阳性和阴性人群中，两组之间的OS没有显着差异。HER2无效和低HER2患者的客观缓解率（ORR）为22.5％和9.1％（p=0.09）。和32.0%和10.5%(p=0.03)，分别,在接受eribulin治疗的患者中，激素阳性病例。在激素阴性患者中未观察到反应。卡培他滨治疗HER2无效和低HER2患者的总ORR为26.8%和15.2%(p=0.23)。分别,激素阳性病例分别为27.3%和16.1%(p=0.28)；25.0%和0%(p=1.0)，分别,激素阴性病例。
结论：Eribulin和卡培他滨敏感性可能因HER2低HER2和无HER2乳腺癌患者的HER2表达而异。低HER2组和无HER2组的预后相似。
